Trial · NCT06547151
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Subjects Who Achieved the Primary Composite Endpoint at Week 14 | 14 weeks | The composite efficacy endpoint is defined as: Subject had a reduction from baseline in total daily dose of oral calcium supplementation of at least 50%, and an albumin-adjusted total serum calcium concentration level between 8.0 mg/dL (incl.) and 10.0 mg/dL (incl.), and no increase from baseline in vitamin D metabolite/analog |
| Secondary | Albumin-adjusted serum calcium | Week 4 to Week 14 | Proportion of participants who achieved albumin-adjusted serum calcium concentrations above, below, or in the range of 8.0 mg/dl and 10.0 mg/dl during Dose Maintenance. |
| Secondary | Urinary Calcium Excretion | Week 14 | Change From Baseline in Urinary Calcium Excretion |
| Secondary | Urine calcium excretion above 300mg/24h | Week 4 to Week 14 | Incidence of increase in urine calcium excretion (\>300 mg/24h) during Dose Maintenance |
| Secondary | GI symptoms | Week 4 to Week 14 | Incidence of GI symptoms associated with calcium intake |
| Secondary | Symptoms associated with hypocalcemia | Week 4 to Week 14 | Incidence of symptoms associated with hypocalcemia |
| Secondary | Hypoparathyroidism Patient Experience Scale (HPES)- Experience (HPES) - Symptom | Week 14 | Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) - Symptom total score at Week 14 |
| Secondary | HPES - Impact | Week 14 | Change from baseline in HPES - Impact total score at Week 14 |
| Secondary | HPES - Symptom - Physical Domain | Week 14 | Change from baseline HPES - Symptom - Physical Domain score at Week 14 |
| Secondary | HPES - Symptom - Cognitive Domain | Week 14 | Change from baseline in HPES - Symptom - Cognitive Domain score at Week 14 |
| Secondary | HPES - Impact - Physical Functioning Domain | eek 14 | Change from baseline in HPES - Impact - Physical Functioning Domain score at Week 14 |
| Secondary | HPES - Impact - Daily Life Domain | Week 14 | Change from baseline in HPES - Impact - Daily Life Domain score at Week 14 |
| Secondary | HPES - Impact - Psychological Well-Being Domain | Week 14 | Change from baseline in HPES - Impact - Psychological Well-Being Domain score at Week 14 |
| Secondary | HPES - Impact - Social Life and Relationships Domain | Week 14 | Change from baseline in HPES - Impact - Social Life and Relationships Domain score at Week 14 |
| Secondary | 36-item Short Form (SF-36) survey | Week 14 | Change From baseline in health-related quality-of-life measured with 36-item Short Form (SF-36) survey at Week 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06547151/registered